Progress in immunotherapy of head and neck squamous cell carcinoma

Research output: Contribution to journalReview article

Abstract

Squamous cell carcinoma of the mucosal surfaces of the head and neck area exhibits a complex interaction with the host immune system that plays an important part in the evolution of the malignant process, in the resistance to different therapeutic modalities, and the ability of tumor cells to metastasize to distant organs. The recent advances in tumor immunology have transformed the field in onco-immunology from using non-specific immune-stimulant agents such as interferon and interleukins to the area of rationally targeted immunotherapy such as immune checkpoint inhibitors, which have shown promising results in early phase clinical trials.

Original languageEnglish (US)
Pages (from-to)226-230
Number of pages5
JournalCurrent Molecular Pharmacology
Volume9
Issue number3
DOIs
StatePublished - Aug 1 2016

Fingerprint

Allergy and Immunology
Immunotherapy
Interleukins
Interferons
Squamous Cell Carcinoma
Immune System
Neoplasms
Neck
Head
Clinical Trials
Carcinoma, squamous cell of head and neck
Therapeutics

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

@article{1845979e02a7442894941018533c997b,
title = "Progress in immunotherapy of head and neck squamous cell carcinoma",
abstract = "Squamous cell carcinoma of the mucosal surfaces of the head and neck area exhibits a complex interaction with the host immune system that plays an important part in the evolution of the malignant process, in the resistance to different therapeutic modalities, and the ability of tumor cells to metastasize to distant organs. The recent advances in tumor immunology have transformed the field in onco-immunology from using non-specific immune-stimulant agents such as interferon and interleukins to the area of rationally targeted immunotherapy such as immune checkpoint inhibitors, which have shown promising results in early phase clinical trials.",
author = "Salah Almokadem",
year = "2016",
month = "8",
day = "1",
doi = "10.2174/1874467208666150716120658",
language = "English (US)",
volume = "9",
pages = "226--230",
journal = "Current Molecular Pharmacology",
issn = "1874-4702",
publisher = "Bentham Science Publishers",
number = "3",

}

Progress in immunotherapy of head and neck squamous cell carcinoma. / Almokadem, Salah.

In: Current Molecular Pharmacology, Vol. 9, No. 3, 01.08.2016, p. 226-230.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Progress in immunotherapy of head and neck squamous cell carcinoma

AU - Almokadem, Salah

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Squamous cell carcinoma of the mucosal surfaces of the head and neck area exhibits a complex interaction with the host immune system that plays an important part in the evolution of the malignant process, in the resistance to different therapeutic modalities, and the ability of tumor cells to metastasize to distant organs. The recent advances in tumor immunology have transformed the field in onco-immunology from using non-specific immune-stimulant agents such as interferon and interleukins to the area of rationally targeted immunotherapy such as immune checkpoint inhibitors, which have shown promising results in early phase clinical trials.

AB - Squamous cell carcinoma of the mucosal surfaces of the head and neck area exhibits a complex interaction with the host immune system that plays an important part in the evolution of the malignant process, in the resistance to different therapeutic modalities, and the ability of tumor cells to metastasize to distant organs. The recent advances in tumor immunology have transformed the field in onco-immunology from using non-specific immune-stimulant agents such as interferon and interleukins to the area of rationally targeted immunotherapy such as immune checkpoint inhibitors, which have shown promising results in early phase clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84989271439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989271439&partnerID=8YFLogxK

U2 - 10.2174/1874467208666150716120658

DO - 10.2174/1874467208666150716120658

M3 - Review article

C2 - 26177644

AN - SCOPUS:84989271439

VL - 9

SP - 226

EP - 230

JO - Current Molecular Pharmacology

JF - Current Molecular Pharmacology

SN - 1874-4702

IS - 3

ER -